We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The world's largest retailer plans to slash the prices of close to 300 generic drugs to $4 for a month's supply, in what is likely the biggest promotion ever to buy cheaper generic alternatives to brand drugs.
Eli Lilly and Amylin Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion recommending approval of exenatide for the treatment of Type 2 diabetes.
Orchid Chemicals & Pharmaceuticals announced that its two sterile facilities for manufacturing cephalosporin formulations and active pharmaceutical ingredients located in near its headquarters in Chennai, India, have received approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).
Taiwan has shown the capability to produce HIV/AIDS vaccines, with the locally-developed products now ready for clinical testing on humans, world-renowned AIDS specialist Dr David Ho said.
Elder Pharmaceuticals, a Rs 375-core Mumbai based pharma major, is setting up a joint venture in Ghana for manufacturing pharmaceutical formulations for marketing in Ghana and nearby countries.
Inex Pharmaceuticals Corporation announced that at its Special Meeting of Shareholders held yesterday, shareholders of INEX approved the Plan of Arrangement to spin-out all of the Company's technology, products, cash and partnerships into a new company, Tekmira Pharmaceuticals Corporation ("Tekmira").
Alliance Pharma plc, a speciality pharmaceutical company, has acquired marketing rights in the UK and Ireland for the woundcare treatment Permitabs, adding a further product to the company's rapidly growing dermatology portfolio.
Sebivo® (telbivudine), a new treatment for patients with chronic hepatitis B shown to deliver more rapid and profound viral suppression than lamivudine, has received approval in Switzerland.
Vaccine developer Avant Immunotherapeutics Inc. said that GlaxoSmithKline PLC has paid royalties on its sales of Rotarix rotavirus vaccine in Australia and certain European countries at the lower of two rates established under the companies' 1997 license agreement.